Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Trading Up 10.1% - Here's What Happened

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) shares rose 10.1% on Wednesday . The stock traded as high as $29.79 and last traded at $29.79. Approximately 300 shares were traded during trading, an increase of 210% from the average daily volume of 97 shares. The stock had previously closed at $27.06.

Swedish Orphan Biovitrum Price Performance

The company has a current ratio of 1.04, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $10.61 billion, a P/E ratio of 25.03 and a beta of 0.42. The company's fifty day simple moving average is $30.05 and its 200 day simple moving average is $29.35.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.06. The firm had revenue of $649.61 million for the quarter, compared to the consensus estimate of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.93%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.